Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Marin

Showing results (111-120 of 180) with videos related to

Pageof 18
Sort By:
Frontiers in Immunology|November 9, 2018
Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood TransplantationKai Cao, David Marin, Takuye Sekine, et al.
Blood|October 21, 2016
KIR gene haplotype: an independent predictor of clinical outcome in MDS patientsKate Stringaris, David Marin, A John Barrett, et al.
Cancer|January 20, 2021
Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndromeBetül Oran, Rima M Saliba, Rohtesh S Mehta, et al.
Blood|November 9, 2016
A subset of virus-specific CD161<sup>+</sup> T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AMLAbdullah Alsuliman, Muharrem Muftuoglu, Ahmad Khoder, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 17, 2010
Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantationPaula Garland, Hugues de Lavallade, Takuya Sekine, et al.
American Journal of Hematology|January 5, 2017
Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantationSameh Gaballa, Rima Saliba, Betul Oran, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 4, 2019
Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up ResultsKamal Chamoun, Denái R Milton, Celina Ledesma, et al.
Blood Advances|January 24, 2024
Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantationCurtis Marcoux, Rima M Saliba, Whitney Wallis, et al.
Leukemia & Lymphoma|October 17, 2015
Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphomaPhilip A Thompson, Travis Perera, David Marin, et al.
Bone Marrow Transplantation|May 17, 2023
Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplantTaha Al-Juhaishi, Yingjun Wang, Denái R Milton, et al.
Pageof 18

Showing results (111-120 of 180) with videos related to

Sort By:
Pageof 18
Frontiers in Immunology|November 9, 2018
Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood TransplantationKai Cao, David Marin, Takuye Sekine, et al.
Blood|October 21, 2016
KIR gene haplotype: an independent predictor of clinical outcome in MDS patientsKate Stringaris, David Marin, A John Barrett, et al.
Cancer|January 20, 2021
Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndromeBetül Oran, Rima M Saliba, Rohtesh S Mehta, et al.
Blood|November 9, 2016
A subset of virus-specific CD161<sup>+</sup> T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AMLAbdullah Alsuliman, Muharrem Muftuoglu, Ahmad Khoder, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 17, 2010
Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantationPaula Garland, Hugues de Lavallade, Takuya Sekine, et al.
American Journal of Hematology|January 5, 2017
Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantationSameh Gaballa, Rima Saliba, Betul Oran, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 4, 2019
Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up ResultsKamal Chamoun, Denái R Milton, Celina Ledesma, et al.
Blood Advances|January 24, 2024
Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantationCurtis Marcoux, Rima M Saliba, Whitney Wallis, et al.
Leukemia & Lymphoma|October 17, 2015
Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphomaPhilip A Thompson, Travis Perera, David Marin, et al.
Bone Marrow Transplantation|May 17, 2023
Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplantTaha Al-Juhaishi, Yingjun Wang, Denái R Milton, et al.
Pageof 18